Masaru Matsuda - Nov 18, 2022 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Role
Reporting person's title: Senior Vice President and General Counsel
Signature
/s/ Scott L. Burrows, Attorney-in-fact for Matsuda Masaru
Stock symbol
ARQT
Transactions as of
Nov 18, 2022
Transactions value $
-$31,289
Form type
4
Date filed
11/22/2022, 06:06 PM
Previous filing
Jun 2, 2022
Next filing
Mar 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Award $0 +4.88K +29.76% $0.00 21.3K Nov 18, 2022 Direct F1, F2
transaction ARQT Common Stock Sale -$31.3K -1.72K -8.09% $18.19 19.5K Nov 21, 2022 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance stock units ("PSUs") initially granted on January 3, 2022, that were subject to a performance-based vesting condition. The vesting condition was determined to be satisfied on November 18, 2022. The PSUs will vest fully on May 27, 2025, subject to the Reporting Person's continued service to the Issuer on such vesting date.
F2 Includes 13,300 Restricted Stock Units ("RSUs").
F3 Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the PSUs, the shares were sold upon the vesting of the PSUs solely to cover applicable withholding taxes.

Remarks:

Reporting person's title: Senior Vice President and General Counsel